Showing all 2 results
DABIGATRAN TABLETS
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Tartaric Acid-Cored Pellet Formulation, packed exclusively in highly specialized, moisture-blocking Alu-Alu blister strips with integrated desiccants to ensure the absolute chemical survival of the intensely hygroscopic prodrug.
Active Ingredient Strength Primary Clinical Function Dabigatran Etexilate Mesylate USP/Ph.Eur. 75 mg / 110 mg The Renal & Geriatric Anchor: The strictly mandated dose reductions utilized for elderly patients (over 80 years old), patients with moderate renal impairment, or those at an elevated risk of hemorrhagic bleeding. Dabigatran Etexilate Mesylate USP/Ph.Eur. 150 mg The Cardiovascular Macrodose: The massive, globally standardized therapeutic payload required for the aggressive, daily prevention of stroke and systemic embolism in Non-Valvular Atrial Fibrillation (NVAF). Excipients Tartaric Acid (Core) / Hypromellose / Talc / Hydroxypropyl Cellulose / Dimethicone Acidic Microenvironment Generator / Polymer Binder / Glidant / Film-Coating (Engineered specifically utilizing advanced Fluid-Bed Pellet Coating. The tartaric acid core is isolated with a polymer layer, then coated with the Dabigatran API, and sealed again. This prevents the acid from prematurely degrading the drug before it reaches the patient’s stomach) *Pack Sizes: 10×10 Specialized Alu-Alu Blisters or Heavy-Gauge HDPE Bottles with Desiccant Caps (Optimized specifically for absolute moisture defense).
Rivaroxaban Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute stability of the potent DOAC molecule.
Active Ingredient Strength Primary Clinical Function Rivaroxaban INN/Ph.Eur. 2.5 mg Vascular Dose: Co-administered with Aspirin to prevent major cardiovascular events in CAD/PAD. Rivaroxaban INN/Ph.Eur. 10 mg Surgical Prophylaxis: Prevention of DVT following knee or hip replacement surgery. Rivaroxaban INN/Ph.Eur. 15 mg / 20 mg Global Clinical Standard: Treatment of acute DVT/PE and stroke prevention in Atrial Fibrillation. Excipients Microcrystalline Cellulose / Croscarmellose Sodium / Hypromellose / Sodium Lauryl Sulfate / Magnesium Stearate Diluent / Superdisintegrant / Surfactant (Engineered for optimal solubilization and synchronized gastrointestinal absorption) *Pack Sizes: 10×10 Alu-Alu Blisters or 14/28/30-Tablet Blisters (Optimized specifically for strict chronic cardiology and acute post-op dispensing regimens).
